2. Protein Tyrosine Kinase/RTK Apoptosis
  3. IGF-1R Apoptosis
  4. Dalotuzumab

Dalotuzumab  (Synonyms: MK-0646; h7C10)

Cat. No.: HY-P99284 Purity: 97.43%
COA

Molarity Calculator

Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo.

For research use only. We do not sell to patients.

Dalotuzumab Chemical Structure

Dalotuzumab Chemical Structure

CAS No. : 1005389-60-5

Size Price Stock Quantity
1 mg USD 300 In-stock
5 mg USD 780 In-stock
10 mg USD 1250 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Dalotuzumab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo[1][2][3].

In Vitro

Dalotuzumab (h7C10; 33 nM; 24 h) inhibits IGF-1- and IGF-2-induced proliferation of MCF7 estrogen-dependent breast cancer cells with IC50 values of 4.2 and 3.1 nM, respectively[1].
Dalotuzumab (33 nM; 24 h) induces cycle arrest and inhibits autophosphorylation of the IGF-IR and IRS-1, in MCF7 cells (IGF-1-induced)[1].
Dalotuzumab increases NK cell-mediated lysis of MCF7 and A459 cells by 26 and 25%, respectively[1].
Dalotuzumab (MK-0646; 10 µg/mL; 24, 48 h) abrogates the anti-apoptotic effect of IGF1 in endometrial cancer cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Dalotuzumab Related Antibodies

Cell Proliferation Assay[1]

Cell Line: MCF7 cells (IGF-1 and IGF-2-induced)
Concentration: 33 nM
Incubation Time: 24 h
Result: Showed anti-proliferation activity to IGF-1- and IGF-2-induced MCF7, with IC50 values of 4.2 and 3.1 nM, respectively.

Cell Cycle Analysis[1]

Cell Line: MCF7 cells (IGF-1-induced)
Concentration: 33 nM
Incubation Time: 24 h
Result: Prevented cell cycle progression from the G1 to S and G2/M phases.

Apoptosis Analysis[2]

Cell Line: ECC-1 and USPC-1 cells (IGF-1-induced)
Concentration: 10 µg/mL
Incubation Time: 24, 48 h
Result: Reversed the effect of IGF1 on caspase-3 cleavage (Caspase-3 is activated in apoptotic cells and cleaves several cellular proteins, including PARP).

Western Blot Analysis[1]

Cell Line: MCF7 cells (IGF-1-induced)
Concentration: 33 nM
Incubation Time: 24 h
Result: Led to a decrease of phosphorylation for both β-chain and IRS-1.
In Vivo

Dalotuzumab (h7C10; i.p.; 250 µg/mice for the first time, then 125 µg/mice twice weekly for 40 days) shows anti-tumor effects on MCF-7 and A549 xenograft tumor models[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Swiss Nude mice (MCF-7 and A549 xenograft tumor models)[1].
Dosage: 125 and 250 (first time) µg/mice
Administration: Intraperitoneal injection; 250 µg/mice for the first time, then 125 µg/mice twice weekly for 40 days
Result: Led to average tumor volume at 6 weeks post-cell injection was reduced by 70% and 72% in the MCF-7 and A549 models, respectively.
Clinical Trial
Molecular Weight

146.4 (kDa)

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Dalotuzumab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation

Purity: 97.43%

COA (232 KB)

Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Dalotuzumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Dalotuzumab1005389-60-5MK-0646 h7C10MK0646MK 0646IGF-1RApoptosisInsulin-like growth factor-1 receptorMCF7 cellNSCLC A459cancerproliferationECC-1 cellUSPC-1 cellapoptosisInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Dalotuzumab
Cat. No.:
HY-P99284
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.